Clinical trial
A Phase 1 Study to Assess the Safety, Radiation Dosimetry and Biodistribution, and Basic Pharmacokinetics of [18F]GEH121224 and Determine the Optimal Timing of Imaging in Patients With Locally Advanced or Metastatic Breast Cancer.
Name
GE-226-004
Description
The study described in this protocol is a Phase 1, single center clinical trial to evaluate the safety and potential of \[18F\]GEH121224 as a PET radiotracer for the diagnostic imaging of HER2 positive breast cancer lesions. A group of 6 patients will be selected to perform a dosimetry study with \[18F\]GEH121224 followed by another group of 6 patients in a test-retest study. The results of this study will provide crucial information to guide the development of \[18F\]GEH121224 for the detection of HER2 status in advanced breast cancer patients. This study will use established methods for characterizing the radiation dosimetry, biodistribution and basic pharmacokinetics of a radiotracer.
Trial arms
Trial start
2025-01-01
Estimated PCD
2025-12-01
Trial end
2025-12-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
GEH121224 (18F) Injection
Single GEH121224 (18F) Injection
Arms:
[18F]GEH121224 - Group 1 - Biodistribution, [18F]GEH121224 - Group 2 - Reproducibility
Dynamic and Static - PET/CT Scan
Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
Arms:
[18F]GEH121224 - Group 1 - Biodistribution
Static - PET/CT Scan
Group 2: Static whole-body scans
Arms:
[18F]GEH121224 - Group 2 - Reproducibility
Size
12
Primary endpoint
Specific absorbed dose to the target lesions, specific absorbed dose per organ, and total effective dose of [18F]GEH121224.
6 months
Change in injection site status following administration of [18F]GEH121224
Before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Occurrence of Adverse Events (AEs) following administration of [18F]GEH121224
6 months
Changes in heart rate as beats per minute following administration of [18F]GEH121224
Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Changes in blood pressure in mmHg following administration of [18F]GEH121224
Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Changes in temperature as degree C following administration of [18F]GEH121224
Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Changes in respiration rate as breaths per minute following administration of [18F]GEH121224
Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of [18F]GEH121224
Baseline, before [18F]GEH121224 administration, immediately after single whole body PET/CT scans
Eligibility criteria
Inclusion Criteria:
* Female patients aged ≥18 years
* Willingness and ability to comply with study procedures and signed and dated informed consent
* For women of child-bearing potential, negative urine pregnancy test at screening and o on the day of investigational medicinal product (IMP) administration (with the result known before IMP administration) and willingness to use contraception (barrier, abstinence, non-hormonal) for 3 weeks after injection of \[18F\]GEH121224
* Life expectancy \>3 months
* Diagnosis of locally advanced or metastatic breast cancer
* Target lesion diameter of ≥15 mm that has not been previously treated with radiotherapy
* Histologically confirmed locally advanced/metastatic breast cancer with a biopsy within the past 12 months confirming HER2-positive status by either IHC or FISH from primary tumor
* Previously received no more than 1 prior lines of systemic chemotherapy (including anti HER2 therapy) for metastatic breast cancer
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
* Adequate organ function as defined by:
Hemoglobin ≥10 g/dL White blood cell count ≥3.0 × 109/L Platelet count ≥75 × 109/L Serum creatinine ≤1.4 mg/dL Aspartate aminotransferase and alanine aminotransferase ≤2× upper limit of normal (ULN) Total bilirubin ≤2× ULN or 3.0 mg/dL in patients with Gilbert's syndrome
* At least one lesion is fluorodeoxyglucose (FDG)-avid
Exclusion Criteria:
* Patient has a primary non-breast malignancy (small dermatological malignancies such as basal cell carcinoma \<10 mm are allowed)
* Pregnancy or breast-feeding or, for women of child-bearing potential, unwillingness to use an acceptable form of birth control
* Chronically active hepatitis B or C
* Current history of drug or alcohol abuse or any active liver disease
* Administration of other IMP within 30 days of screening
* Systemic therapy including anti-HER2 therapy within 2 weeks before enrollment
* Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
* History of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis)
* Evidence of significant medical condition, ongoing severe disease, or laboratory finding that, in the opinion of the Investigator, makes it undesirable for the patient to participate in the study
* Severe claustrophobia, inability to lie flat or fit into the scanner (e.g., body weight ≥350 lbs \[160 kg\]), or any other inability to tolerate the PET scan
* Known allergies to any product used in this study or any constituents of GEH121224 (18F) Injection
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'Patients will be enrolled into 1 of 2 groups in a sequential manner. Group 1 will allow to study \\[18F\\]GEH121224 Biodistribution and Radiation Dosimetry. Group 2 will allow to study \\[18F\\]GEH121224 PET/CT Scan Test Retest.', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 12, 'type': 'ESTIMATED'}}
Updated at
2024-02-23
1 organization
1 product
1 indication
Organization
GE HealthcareProduct
GEH121224Indication
Breast Cancer